Latest papers

Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.

Antibody-based vascular tumor targeting.

Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.

RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab.

Bulk flow and diffusion revisited, and clinical applications.

New Antibody Conjugates in Cancer Therapy

Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience.

Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes.

Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site

[Radiolabeled antibodies for cancer treatment].

Estimation of yttrium-90 Zevalin tumor-absorbed dose in ocular adnexal lymphoma using quantitative indium-111 Zevalin radionuclide imaging.

[Use of multimodal treatment for early-stage follicular lymphoma].

[Current treatment of follicular lymphoma]

Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.

Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.

First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.

Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin.

Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.

Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.

Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.